Evidence map›Paper›PMID 39913188›Full record

ArticleJCI insight2025

GADD45α is a direct target of TFEB and contributes to tacrolimus-induced chronic nephrotoxicity.

Ping Gao, Xinwei Cheng, Maochang Liu, Hui Peng, Guodong Li, Tianze Shang, Jianqiao Wang, Qianyan Gao, Chenglong Zhu, Zhenpeng Qiu and 1 more

Abstract read
In one paragraph

Article in JCI insight, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Tacrolimus inhibits CVB3-targeted regulation of TFEB by PPP3/calcineurin.Frontiers in cellular and infection microbiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ping GaoSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, China.
Xinwei ChengTongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Maochang LiuWuhan Children's Hospital, Tongji Medical College, and.
Hui PengWuhan Children's Hospital, Tongji Medical College, and.
Guodong LiTongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Tianze ShangTongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jianqiao WangTongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Qianyan GaoTongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Chenglong ZhuTongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zhenpeng QiuSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, China.
Chengliang ZhangTongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tacrolimus-induced chronic nephrotoxicity (TICN) hinders long-term use of tacrolimus, but its mechanism remains unclear. Tacrolimus exerts its pharmacological effect by inhibiting calcineurin and its substrate nuclear factor of activated T cells. Whether the inhibition of other calcineurin substrates is related to TICN remains to be explored. Transcription factor EB (TFEB), a substrate of calcineurin, plays a crucial role in homeostasis. Herein, we found that tacrolimus inhibited TFEB nuclear translocation and activity in mouse kidneys and HK-2 cells. Then, TFEB gain and loss of function rescued and exacerbated, respectively, the effect of tacrolimus in HK-2 cells. Furthermore, TFEB activation by both phosphorylation site mutation and agonist rescued TICN in mice. To elucidate the mechanism of TFEB, we analyzed ChIP-Seq data. We identified growth arrest and DNA damage-inducible 45α (GADD45α) as a transcriptional target of TFEB via ChIP and dual-luciferase reporter assays. Then we revealed that GADD45α overexpression rescued DNA damage and kidney injury caused by tacrolimus or TFEB knockdown in vitro and vice versa. The protective effect of GADD45α against TICN and DNA damage was further demonstrated by overexpressing it in mice. In conclusion, the persistent inhibition of the TFEB/GADD45α pathway by tacrolimus contributes to TICN. This study identifies a specific target for intervention in TICN.

Indexed as

Basic Helix-Loop-Helix Leucine Zipper Transcription FactorsCell Cycle ProteinsImmunosuppressive AgentsKidney DiseasesNuclear ProteinsTacrolimusAnimalsCell LineDNA DamageGADD45 ProteinsHumansKidneyMaleMiceMice, Inbred C57BLBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsCell Cycle ProteinsGadd45a protein, mouseGADD45 ProteinsImmunosuppressive AgentsNuclear ProteinsTacrolimusTcfeb protein, mouseTFEB protein, humanNephrologyTherapeuticsToxicology

Identifiers

PMID39913188
PMCPMC11949043

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.